Your session is about to expire
← Back to Search
Naproxen/Normal saline for Birth Control
N/A
Waitlist Available
Led By Susan Dunlow, MD
Research Sponsored by Walter Reed National Military Medical Center
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 30 days post insertion
Awards & highlights
Study Summary
To compare the efficacy of intrauterine lidocaine and oral naproxen sodium on discomfort and pain of patients undergoing intrauterine device insertion.
Eligible Conditions
- Birth Control
- Pain
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ 30 days post insertion
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~30 days post insertion
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Primary outcome measures
Intrauterine Devices
Secondary outcome measures
Difficulty IUD Insertion
Patient Satisfaction With IUD
Pain
+1 moreTrial Design
4Treatment groups
Experimental Treatment
Group I: Placebo oral medication/LidocaineExperimental Treatment2 Interventions
Patient will receive placebo oral medication and intrauterine lidocaine prior to IUD insertion
Group II: PlaceboExperimental Treatment1 Intervention
Patient will receive placebo oral medication and intrauterine normal saline prior to IUD insertion
Group III: Naproxen/Normal salineExperimental Treatment2 Interventions
Patient will receive naproxen and intrauterine normal saline prior to IUD insertion
Group IV: Naproxen/LidocaineExperimental Treatment2 Interventions
Patient will receive naproxen and intrauterine lidocaine prior to IUD insertion
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Naproxen
FDA approved
Lidocaine
FDA approved
placebo
2010
Completed Phase 4
~6580
Find a Location
Who is running the clinical trial?
Walter Reed National Military Medical CenterLead Sponsor
138 Previous Clinical Trials
32,828 Total Patients Enrolled
Susan Dunlow, MDPrincipal InvestigatorWRNMMC
Share this study with friends
Copy Link
Messenger